Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element
Open Access
- 21 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 48 (9), 4741-4755
- https://doi.org/10.1093/nar/gkaa178
Abstract
Androgen receptor (AR) action is a hallmark of prostate cancer (PCa) with androgen deprivation being standard therapy. Yet, resistance arises and aberrant AR signaling promotes disease. We sought compounds that inhibited genes driving cancer but not normal growth and hypothesized that genes with consensus androgen response elements (cAREs) drive proliferation but genes with selective elements (sAREs) promote differentiation. In a high-throughput promoter-dependent drug screen, doxorubicin (dox) exhibited this ability, acting on DNA rather than AR. This dox effect was observed at low doses for multiple AR target genes in multiple PCa cell lines and also occurred in vivo. Transcriptomic analyses revealed that low dox downregulated cell cycle genes while high dox upregulated DNA damage response genes. In chromatin immunoprecipitation (ChIP) assays with low dox, AR binding to sARE-containing enhancers increased, whereas AR was lost from cAREs. Further, ChIP-seq analysis revealed a subset of genes for which AR binding in low dox increased at pre-existing sites that included sites for prostate-specific factors such as FOXA1. AR dependence on cofactors at sAREs may be the basis for differential modulation by dox that preserves expression of genes for survival but not cancer progression. Repurposing of dox may provide unique opportunities for PCa treatment.Funding Information
- Department of Defense (W81XWH-11-1-0219, W81XWH-14-1-0292, W81XWH-11-1-0360, W81XWH-17-1-0155)
- National Institutes of Health (RO1 DK56356, P50 CA69568, T32 CA09676)
- University of Michigan
This publication has 63 references indexed in Scilit:
- Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate CancerInternational Journal of Molecular Sciences, 2013
- Doxorubicin Enhances Nucleosome Turnover around PromotersCurrent Biology, 2013
- Genome-wide structure and organization of eukaryotic pre-initiation complexesNature, 2012
- Integrative genomics viewerNature Biotechnology, 2011
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerTrends in Endocrinology & Metabolism, 2010
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate CancerCell, 2009
- Differential Presentation of Protein Interaction Surfaces on the Androgen Receptor Defines the Pharmacological Actions of Bound LigandsCell Chemical Biology, 2009
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999